Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis
暂无分享,去创建一个
Till Acker | Oliver Distler | Ulf Müller-Ladner | Max Gassmann | M. Gassmann | T. Acker | K. Plate | U. Müller-Ladner | R. Gay | S. Gay | M. Matucci-Cerinic | O. Distler | B. Michel | J. Distler | Renate E Gay | Steffen Gay | Jörg H W Distler | Annette Scheid | Astrid Hirth | Janine Rethage | Beat A Michel | Marco Matucci-Cerinic | Karl H Plate | A. Scheid | A. Hirth | J. Rethage | B. Michel
[1] U. Müller-Ladner,et al. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. , 2004, Molecular pharmacology.
[2] Maurizio Cutolo,et al. Raynaud's phenomenon and the role of capillaroscopy. , 2003, Arthritis and rheumatism.
[3] R. Gay,et al. Angiogenic and angiostatic factors in the molecular control of angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[4] S. Cheung,et al. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. , 2003, Cancer research.
[5] J. Korn,et al. Fibrosis in scleroderma. , 2003, Rheumatic diseases clinics of North America.
[6] O. Distler,et al. Non organ based laboratory markers in systemic sclerosis. , 2003, Clinical and experimental rheumatology.
[7] M. Gassmann,et al. Hypoxic up-regulation of erythroid 5-aminolevulinate synthase. , 2003, Blood.
[8] R. Macko,et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. , 2002, The Journal of rheumatology.
[9] Y. Konttinen,et al. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. , 2002, Clinical and experimental rheumatology.
[10] M. Conforti,et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.
[11] R. Wenger,et al. Cellular adaptation to hypoxia: O2‐sensing protein hydroxylases, hypoxia‐inducible transcription factors, and O2‐regulated gene expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] P. Carmeliet,et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.
[13] M. Gassmann,et al. Physiologically low oxygen concentrations determined in fetal skin regulate hypoxia‐inducible factor 1 and transforming growth factor β3 , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] A. Ogata,et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma , 2002, British journal of haematology.
[15] T. Hofer,et al. Oxygen sensing, HIF-1alpha stabilization and potential therapeutic strategies. , 2002, Pflugers Archiv : European journal of physiology.
[16] T. Hofer,et al. Oxygen sensing, HIF-1α stabilization and potential therapeutic strategies , 2002, Pflügers Archiv - European Journal of Physiology.
[17] M. Gassmann,et al. HIF‐1 is expressed in normoxic tissue and displays an organ‐specific regulation under systemic hypoxia , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] U. Müller-Ladner,et al. Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. , 2001, Arthritis and rheumatism.
[19] M. Gassmann,et al. Induction of HIF–1α in response to hypoxia is instantaneous , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] E. Manseau,et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. , 2001, The American journal of pathology.
[21] Till Acker,et al. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function , 2000, Oncogene.
[22] Peter Carmeliet,et al. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? , 2000, Nature Medicine.
[23] L. Hornez,et al. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.
[24] M. Gassmann,et al. Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair , 2000, Pediatric Surgery International.
[25] G. Neufeld,et al. Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] M. Gassmann,et al. General applicability of chicken egg yolk antibodies: the performance of IgY immunoglobulins raised against the hypoxia‐inducible factor 1α , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[27] S M Evans,et al. Interlaboratory variation in oxygen tension measurement by Eppendorf “Histograph” and comparison with hypoxic marker , 1997, Journal of surgical oncology.
[28] E. Leroy. SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .
[29] C. Strange,et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. , 1995, The Journal of rheumatology.
[30] C. Little,et al. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[31] H. Dvorak,et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. , 1995, The Journal of investigative dermatology.
[32] K. Alitalo,et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. , 1994, The Journal of biological chemistry.
[33] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[34] M. Goto,et al. Production of intracellular and extracellular interleukin-1 alpha and interleukin-1 beta by peripheral blood monocytes from patients with connective tissue diseases. , 1991, Annals of the rheumatic diseases.
[35] M. Murakami,et al. Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. , 1990, Arthritis and rheumatism.
[36] R. Gay,et al. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. , 1989, The Journal of investigative dermatology.
[37] T. Medsger,et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.
[38] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[39] James F. Fries,et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.